ライフサイエンスコーパス: CABG

1 CABG plus medical therapy was associated with a lower in

2 CABG procedures in the EXCEL compared with the SYNTAX tr

3 CABG was found to be superior to PCI for the primary com

4 CABG was performed with or without cardiopulmonary bypas

5 stacute care use was present in 9662 (86.2%) CABG episodes and 4242 (69.3%) AVR episodes, with respec

6 following colectomy (OR 1.1 95%CI 1.1-1.3), CABG (OR 1.4, 95%CI 1.2-1.5), and lung resection (OR 1.4

7 my, 40,328 (14%) lung resection, 16,127 (6%) CABG and 10,602 (3%) esophagectomy cases.

8 o underwent a colectomy (n = 88,778, 29.6%), CABG (n = 109,564, 36.6%), lung resection (n = 30,401, 1

9 Among 923 CABG patients, 652 and 271 patients underwent on-pump an

10 s (95% confidence intervals) differed across CABG categories for MACE (no CABG 1.3% [0.5% to 2.2%], i

11 >=1 SVGs were randomly assigned (1:1) after CABG to ticagrelor or placebo added to standard aspirin

12 estimated in 17% after PCI versus 10% after CABG (HR 1.73 [95% CI 1.25-2.40]; p=0.0009).

13 ients had died after PCI and 212 (24%) after CABG (hazard ratio 1.19 [95% CI 0.99-1.43], p=0.066).

14 as estimated in 8% after PCI versus 3% after CABG (HR 2.99 [95% CI 1.66-5.39]; p=0.0002); and repeat

15 died after PCI versus 98 (28%) of 348 after CABG (0.92 [0.69-1.22], p(interaction)=0.023).

16 died after PCI versus 114 (21%) of 549 after CABG (hazard ratio 1.42 [95% CI 1.11-1.81]), and among p

17 as estimated in 9% after PCI versus 9% after CABG (HR 1.08 [95% CI 0.74-1.59]; p=0.68); non-procedura

18 and nonfatal stroke) and 1-year angina after CABG and PCI using baseline covariates and treatment int

19 al factors were associated with angina after CABG: younger age, worse preoperative SAQ angina frequen

20 ding the need for coronary angiography after CABG.

21 rtality at 10 years tended to be lower after CABG than after PCI, with a similar treatment effect for

22 sociated with cardiovascular mortality after CABG (adjusted HR: 11.94; 95% CI: 4.84 to 29.47) but not

23 was strongly associated with mortality after CABG but not after PCI.

24 ion, whereas their impact on mortality after CABG was limited to 1 year.

25 with increasing SS after PCI, but not after CABG.

26 race and sex on postoperative outcomes after CABG.

27 fter PCI and 56 of 923 (6.1%) patients after CABG (difference -2.4%; 95% confidence interval [CI]: -4

28 ary ischemia requiring in-hospital PCI after CABG were compared with patients who did not need PCI.

29 utaneous coronary interventions (PCIs) after CABG are scarce.

30 ation was more frequent after PCI than after CABG (16.9% vs. 10.0%; difference, 6.9 percentage points

31 ents were less frequent after PCI than after CABG (3.3% vs. 5.2%; difference, -1.9 percentage points;

32 Self-reported angina 1 year after CABG is associated with younger age, worse baseline SAQ

33 aspirin improves SVG patency at 1 year after CABG.

34 iated with self-reported angina 1 year after CABG.

35 did not reduce SVG occlusion at 1 year after CABG.

36 tistic 0.73, 95%CI 0.72-0.74, p < 0.001) and CABG (C-statistic 0.70, 95%CI 0.68-0.73, p < 0.001), but

37 definition were higher in the PCI (5.7%) and CABG (16.5%) arms.

38 ]), PCI (OR: 0.80, 95% CI: [0.67, 0.96]) and CABG (OR: 0.70, 95% CI: [0.52, 0.93]) in symptomatic HIV

39 PCI was never superior to CABG, and CABG was superior to PCI for MACE in 54.5% of patients a

40 Percutaneous coronary intervention and CABG show comparable safety in patients with LMCA stenos

41 rdial infarction was similar between PCI and CABG (18.6% versus 16.7%, respectively; P=0.40) and did

42 ifference in early mortality between PCI and CABG (2.4% vs. 2.3%; p = 0.721) after matching.

43 cardiovascular mortality after both PCI and CABG (p(interaction) = 0.86).

44 o control group for catheterization, PCI and CABG (respectively OR: 0.90, 95% CI: [0.78, 1.05], OR: 1

45 les to identify index admissions for PCI and CABG from 2013 through 2016 at BPCI hospitals and matche

46 In the PCI and CABG groups, the incidences of definite cardiovascular d

47 int was similar after treatment with PCI and CABG in diabetic patients (20.7% vs. 19.3%, respectively

48 o assess contemporary outcomes after PCI and CABG in patients with left main CAD according to SS and

49 Thus, PCI and CABG mechanisms may differ.

50 f EXCEL, these findings suggest that PCI and CABG provide similar intermediate-term outcomes for pati

51 g selected patients with LMCAD, both PCI and CABG result in similar QoL improvement through 36 months

52 The rates of PMI after PCI and CABG vary greatly with different definitions.

53 ipation in episode-based payment for PCI and CABG was not associated with changes in patient selectio

54 Differences between PCI and CABG were assessed using longitudinal random-effect grow

55 as no significant difference between PCI and CABG with respect to the rate of the composite outcome o

56 grates the positive features of both PCI and CABG, albeit requiring 2 procedures rather than 1.

57 For both PCI and CABG, BPCI participation was not associated with changes

58 f 4,519 and 9,716 patients underwent PCI and CABG, respectively.

59 associated with similar hazard after PCI and CABG, whereas PMI(UD) was strongly associated with morta

60 myocardial ischemia, different after PCI and CABG.

61 was found between TAVR and PCI and SAVR and CABG (16.0%; 95% CI 11.1 - 22.9 vs. 14.0%; 95% CI 9.2 -

62 were 169 TAVR and PCI patients, 163 SAVR and CABG patients, 695 TAVR patients, and 633 SAVR patients.

63 PCI is a reasonable alternative to SAVR and CABG.

64 after PCI with everolimus-eluting stents and CABG and was independent of the baseline anatomic comple

65 rst-generation paclitaxel-eluting stents and CABG.

66 year mortality compared with single-arterial CABG in 3,588 propensity-matched pairs (15.1% vs. 17.3%;

67 In contemporary practice, single-arterial CABG is used in 85% of patients and is associated with i

68 Single-arterial CABG patients were older (mean 68 vs. 61 years; p < 0.00

69 y after multiarterial versus single-arterial CABG.

70 th, myocardial infarction, or stroke between CABG and FFR-guided PCI.

71 ted to significantly limit new infarcts, but CABG may do so through providing flow distal to vessel o

72 Patients were categorized by CABG status: no CABG (n = 16,896); index CABG after qual

73 ng stents (PCI group, 948 patients) or CABG (CABG group, 957 patients).

74 he association between 3-way CAD status (CAD-CABG, CAD-NoCABG, NoCAD) and overall retransplant-free s

75 Among SIHD patients with T2DM and no CKD, CABG + OMT significantly reduced MACCE compared with PCI

76 ck/minority patients undergoing a colectomy, CABG, or lung resection who lived in highly socially vul

77 tery bypass graft (CABG) surgery or combined CABG/valve surgeries at a US center.

78 Conventional CABG patients were more likely to be free from repeat re

79 HCR (0.80%) patients and 37 556 conventional CABG patients after exclusions.

80 scularization rates for HCR and conventional CABG after using propensity matching to reduce selection

81 HCR and conventional CABG had no different 6-year mortality rates, but HCR ha

82 s no difference between HCR and conventional CABG in survival at 6 years (80.9% versus 85.8%%, adjust

83 Within 30 days, CABG patients had a 25-fold, a 26-fold, and a 18-fold hi

84 patients with multivessel CAD and diabetes, CABG was associated with improved long-term mortality an

85 ts with multivessel coronary artery disease, CABG was associated with a lower rate of major adverse c

86 ing stent era, studies of racial disparities CABG are outdated.

87 In each CABG category, hazard ratios (95% confidence intervals)

88 ify individuals who will benefit from either CABG or PCI, thereby supporting heart teams, patients, a

89 at enrolled 330 patients undergoing elective CABG.

90 tors for early coronary compromise following CABG.

91 of PCIs were performed within 24 h following CABG.

92 tors of needing an in-hospital PCI following CABG.

93 utcomes of early (in-hospital) PCI following CABG.

94 For CABG, payments at both BPCI and control hospitals decrea

95 two hospitals joined BPCI for PCI and 46 for CABG.

96 70] for PCI and C-index=0.62 [0.58-0.66] for CABG) and good calibration for predicting 5-year major a

97 69] for PCI and C-index=0.71 [0.67-0.75] for CABG).

98 0.69-0.76] for PCI and 0.73 [0.69-0.76] for CABG) and 5-year major adverse cardiovascular events (C-

99 care spending ranged from $3280 to $8186 for CABG and $2246 to $7710 for AVR.

100 difference for COL and 3-fold difference for CABG in index hospitalization cost.

101 165 events) for PCI and 19% (110 events) for CABG (HR 1.58 [95% CI 1.24-2.01]); the HR exceeded the l

102 the utilization of saphenous vein grafts for CABG surgery and provide an overview of the current prac

103 ilateral internal-thoracic-artery grafts for CABG.

104 3 years, 87.1% were male, the indication for CABG was acute coronary syndrome in 31.3%, and 95.2% of

105 could be used in shared decision-making for CABG versus PCI by estimating each patient's personal ou

106 emerging bundled reimbursement programs for CABG, hospitals and physicians should identify strategie

107 Among patients who were scheduled for CABG and had been randomly assigned to undergo bilateral

108 We randomly assigned patients scheduled for CABG to undergo bilateral or single internal-thoracic-ar

109 ability in hospital 90-day episode value for CABG.

110 In general, CABG resulted in greater angina relief, although the abs

111 s without CKD, coronary artery bypass graft (CABG) surgery combined with optimal medical therapy (OMT

112 Coronary artery bypass graft (CABG) surgery is the gold-standard treatment in many pat

113 d conventional coronary artery bypass graft (CABG) surgery medium-term outcomes.

114 rgoing on-pump coronary artery bypass graft (CABG) surgery or combined CABG/valve surgeries at a US c

115 ntion (PCI) or coronary artery bypass graft (CABG) surgery.

116 spine surgery; coronary artery bypass graft (CABG) surgery; and craniotomy at 8 centers between Janua

117 repair (AAA), coronary artery bypass graft (CABG), colectomy, or hip replacement were identified usi

118 lon resection, coronary artery bypass graft (CABG), lung resection, or lower extremity joint replacem

119 y/proctectomy, coronary artery bypass graft (CABG), pancreaticoduodenectomy, lung resection, or esoph

120 plications, or coronary artery bypass graft (CABG), with improved long-term, event-free survival attr

121 n - PCI - and Coronary Artery Bypass Graft - CABG) among groups of population of interest (control, a

122 e following coronary artery bypass grafting (CABG) and aortic valve replacement (AVR) and the relatio

123 amenable to coronary-artery bypass grafting (CABG) and who had a left ventricular ejection fraction o

124 history of coronary artery bypass grafting (CABG) are at high risk for recurrent cardiovascular even

125 n (PCI) and coronary artery bypass grafting (CABG) are considered revascularization procedures, but o

126 us single-arterial coronary bypass grafting (CABG) are debated.

127 or on-pump coronary artery bypass grafting (CABG) at 12 centers in Germany.

128 undergoing coronary artery bypass grafting (CABG) between 2011 and 2018 and to investigate the effec

129 I) group or coronary artery bypass grafting (CABG) group.

130 ry disease, coronary artery bypass grafting (CABG) has shown long-term benefits over percutaneous cor

131 stents with coronary artery bypass grafting (CABG) in patients with de-novo three-vessel and left mai

132 (PCI) with coronary artery bypass grafting (CABG) in patients with diabetes and multivessel coronary

133 ease (MVD), coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention

134 n (PCI) and coronary artery bypass grafting (CABG) is unknown.

135 ver 180 000 coronary artery bypass grafting (CABG) procedures are performed annually, accounting for

136 th off-pump coronary artery bypass grafting (CABG) surgery compared with on-pump surgery particularly

137 rvention (PCI) and coronary bypass grafting (CABG) surgery exist.

138 PCI) versus coronary artery bypass grafting (CABG) surgery in the EXCEL (Evaluation of XIENCE versus

139 o underwent coronary artery bypass grafting (CABG) surgery.

140 rafts after coronary-artery bypass grafting (CABG) surgery.

141 on average, coronary artery bypass grafting (CABG) was superior to percutaneous coronary intervention

142 undergoing coronary artery bypass grafting (CABG) with prior surgical results, in the context of ran

143 OL), 22% in coronary artery bypass grafting (CABG), 19% in Total Hip Arthroplasty, and 18% in Total K

144 colectomy, coronary artery bypass grafting (CABG), hip or knee replacement, or lung resection].

145 mpared with coronary-artery bypass grafting (CABG), in patients with left main coronary artery diseas

146 conduit for coronary-artery bypass grafting (CABG).

147 R group had coronary artery bypass grafting (CABG).

148 PCI) versus coronary artery bypass grafting (CABG).

149 n (PCI) and coronary artery bypass grafting (CABG).

150 lication of coronary artery bypass grafting (CABG).

151 treatment, coronary artery bypass grafting (CABG).

152 ention (CAD-coronary artery bypass grafting [CABG]) and those who did not (CAD-NoCABG) at the time of

153 on [PCI] or coronary artery bypass grafting [CABG]) or optimal medical therapy alone in patients with

154 n=4), coronary artery bypass grafting (HFpEF(CABG), n=5; and HFrEF(CABG), n=5), or left ventricular a

155 bypass grafting (HFpEF(CABG), n=5; and HFrEF(CABG), n=5), or left ventricular assist device implantat

156 However, CABG provided a significant survival benefit in patients

157 frequently in prior CABG patients, however, CABG patients had a lower incidence of pericardial tampo

158 n grafts - the most commonly used conduit in CABG surgery - fail in 40-50% of treated patients by 10

159 nd high postacute care spending hospitals in CABG and AVR episodes.

160 potential long-term benefits of using MAR in CABG patients with renal insufficiency may be offset by

161 y associated with midterm graft occlusion in CABG patients and a cumulative MV score stratifies patie

162 for MACE (no CABG 1.3% [0.5% to 2.2%], index CABG 0.9% [-2.3% to 4.0%], prior CABG 6.4% [0.9% to 12.0

163 by CABG status: no CABG (n = 16,896); index CABG after qualifying ACS, but before randomization (n =

164 for MACE (no CABG 0.86 [0.78 to 0.95], index CABG 0.85 [0.54 to 1.35], prior CABG 0.77 [0.61 to 0.98]

165 r descending artery where minimally invasive CABG was performed, and in the coronary arteries where p

166 re and private payor admissions for isolated CABG from 2014 to 2016 were retrospectively linked to cl

167 who were treated with either PCI or isolated CABG from 2008 to 2017.

168 o, Canada of patients who underwent isolated CABG (n = 23,406).

169 of 1,042,506 patients who underwent isolated CABG between 2011 and 2018.

170 Multiarterial CABG is underused in contemporary surgical revasculariza

171 Multiarterial CABG was associated with lower 10-year myocardial infarc

172 ting for baseline differences, multiarterial CABG was associated with lower 10-year mortality compare

173 ients, 3,647 (14.0%) underwent multiarterial CABG.

174 d reintervention compared with multiarterial CABG.

175 tios (95% confidence intervals) for MACE (no CABG 0.86 [0.78 to 0.95], index CABG 0.85 [0.54 to 1.35]

176 differed across CABG categories for MACE (no CABG 1.3% [0.5% to 2.2%], index CABG 0.9% [-2.3% to 4.0%

177 Patients were categorized by CABG status: no CABG (n = 16,896); index CABG after qualifying ACS, but

178 3 years occurred in 13.6% of PCI and 9.0% of CABG patients (p = 0.046), although no significant inter

179 ty is associated with a long-term benefit of CABG in patients with ischemic cardiomyopathy.

180 The estimated treatment benefit of CABG over PCI varied substantially among patients in the

181 ir differences (ie, the estimated benefit of CABG versus PCI by calculating the absolute risk differe

182 For the comparison of CABG + OMT versus PCI + OMT in the CKD group, there was

183 All comparisons of CABG to PCI or medical therapy that demonstrate survival

184 rdial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone (P

185 e to accurately predict treatment effects of CABG or PCI, questioning a revascularization mechanism f

186 Prior history of CABG (OR 0.33 95%CI 0.35-0.36), previous PCI (OR 0.84 95

187 dered revascularization procedures, but only CABG can prolong life in stable coronary artery disease.

188 CS, but before randomization (n = 1,025); or CABG before the qualifying ACS (n = 1,003).

189 ollowing colectomy (OR 1.1 95%CI 1.1-1.2) or CABG (OR 1.2 95%CI 1.1-1.3), yet there no association of

190 ere enrolled and allocated to PCI (n=598) or CABG (n=603), with 17 subsequently lost to early follow-

191 were randomly assigned to the PCI (n=903) or CABG (n=897) group.

192 randomly assigned (1:1) to the PCI group or CABG group.

193 -eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients).

194 disease randomized to treatment with PCI or CABG in the SYNTAX trial.

195 However, achieving CR after PCI or CABG surgery might not be feasible owing to patient como

196 action between sex and treatment with PCI or CABG that was observed at 5 years was no longer present

197 fferent methods of revascularization (PCI or CABG) against each other or medical treatment in patient

198 econd stage, with assigned treatment (PCI or CABG) and two prespecified effect-modifiers, which were

199 Patients with a history of PCI or CABG, acute myocardial infarction, or an indication for

200 outcome in those eligible for either PCI or CABG.

201 ial infarction) in patients receiving PCI or CABG.

202 nd randomly assigned (1:1) to receive PCI or CABG.

203 imus-eluting or paclitaxel-eluting stents or CABG on a background of optimal medical therapy.

204 =32 to PCI with everolimus-eluting stents or CABG.

205 When compared with PCI, CABG still showed a survival benefit (hazard ratio, 0.82

206 The POPular CABG trial (The Effect of Ticagrelor on Saphenous Vein G

207 Post-CABG PCI was also associated with longer hospitalization

208 ion rates and associated outcomes among post-CABG patients with diabetes.

209 e use of DAPT in patients with diabetes post-CABG in our cohort was high.

210 Predictors of the need for post-CABG PCI were assessed in multivariate regression analys

211 In-hospital post-CABG PCI is uncommon but is associated with significantl

212 eatment of these comorbidities improves post-CABG angina symptoms requires further study.

213 Patients who underwent post-CABG PCI had higher rates of strokes (2.1% vs. 1.6%; p <

214 Bypass) with protocol-specified 1-year post-CABG coronary angiography and SAQ assessments were inclu

215 62.3%) within 4 weeks before the 1-year post-CABG study visit on the SAQ angina frequency domain were

216 y score, smoking, diabetes mellitus, and pre-CABG depression.

217 Prior CABG patients (32% of total cohort) were older (67+/-9 v

218 Prior CABG patients had lower technical (84% versus 89%; P<0.0

219 .2%], index CABG 0.9% [-2.3% to 4.0%], prior CABG 6.4% [0.9% to 12.0%]) and for death (0.4% [-0.1% to

220 nts with (n=1101) and without (n=2317) prior CABG at 21 centers.

221 0.95], index CABG 0.85 [0.54 to 1.35], prior CABG 0.77 [0.61 to 0.98]) and death (0.88 [0.75 to 1.03]

222 The CTO target vessel in prior CABG patients was the right coronary artery (56%), circu

223 ; P<0.001) occurred more frequently in prior CABG patients, however, CABG patients had a lower incide

224 echniques were used more frequently in prior CABG patients.

225 .2+/-1.0; P<0.001) score was higher in prior CABG patients.

226 neous coronary interventions registry, prior CABG patients had lower success rate but similar overall

227 ocumab to statins in ACS patients with prior CABG in a pre-specified analysis of ODYSSEY OUTCOMES (Ev

228 ars, 361 patients (31%) assigned to off-pump CABG and 352 patients (30%) assigned to on-pump CABG had

229 ation (log-rank test: P=0.02) after off-pump CABG and 72% (95% CI, 67-76) versus 77% (95% CI, 74-80)

230 In this randomized trial, off-pump CABG led to lower rates of 5-year survival and event-fre

231 Nonelective admissions and off-pump CABG were the strongest predictors of needing an in-hosp

232 ell, were similar after on-pump and off-pump CABG.

233 (29%) patients randomly assigned to on-pump CABG ( P<0.001).

234 fter off-pump and in 389 (33%) after on-pump CABG (hazard ratio, 1.03; 95% CI, 0.89-1.18; P=0.704).

235 76) versus 77% (95% CI, 74-80) after on-pump CABG (log-rank test: P=0.03), respectively.

236 G and 352 patients (30%) assigned to on-pump CABG had died (hazard ratio off-pump/on-pump CABG, 1.03;

237 CABG had died (hazard ratio off-pump/on-pump CABG, 1.03; 95% CI, 0.89-1.19; P=0.71).

238 urvival and event-free survival than on-pump CABG.

239 patients with renal dysfunction who require CABG.

240 A total of 24 (7%) had CAD requiring CABG, 82 (25%) had CAD not requiring CABG, and the remai

241 quiring CABG, 82 (25%) had CAD not requiring CABG, and the remaining 227 had no CAD.

242 after coronary artery bypass graft surgery (CABG) despite aspirin use.

243 ed for coronary artery bypass graft surgery (CABG) were included.

244 prior coronary artery bypass graft surgery (CABG).

245 lowing coronary artery bypass graft surgery (CABG).

246 ter coronary artery bypass grafting surgery (CABG) are lacking.

247 sus coronary artery bypass grafting surgery (CABG) on mortality at 5 years differed significantly bet

248 tion) occurred more frequently with PCI than CABG (28.0% versus 22.0%, P=0.01), a difference which ro

249 iac tissue samples were collected during the CABG surgery and were analyzed by reverse transcriptase

250 m versus 2.4% and 2.1%, respectively, in the CABG arm.

251 ntly higher in the PCI-DES group than in the CABG group (24.3% [159 deaths] vs. 18.3% [112 deaths]; h

252 CI group and in 19.2% of the patients in the CABG group (difference, 2.8 percentage points; 95% confi

253 e PCI-DES group and 18.7% (72 deaths) in the CABG group (hazard ratio: 1.32; 95% confidence interval:

254 more frequently in the PCI group than in the CABG group (in 13.0% vs. 9.9%; difference, 3.1 percentag

255 alone (182 deaths among 298 patients in the CABG group vs. 209 deaths among 303 patients in the medi

256 the PCI group and 848 (95%) patients in the CABG group.

257 was higher in the FFR-guided PCI versus the CABG group (44.5% versus 31.9%; hazard ratio, 1.60 [95%

258 Thus, CABG may differ from PCI by providing "surgical collater

259 limit for non-inferiority of PCI compared to CABG.

260 to evaluate whether PCI was non-inferior to CABG in the treatment of left main coronary artery disea

261 Non-inferiority of PCI to CABG was defined as the upper limit of the 95% CI of the

262 y-matched analysis of patients randomized to CABG in the SYNTAX (Synergy Between PCI With Taxus and C

263 PCI was never superior to CABG, and CABG was superior to PCI for MACE in 54.5% of

264 and length of stay compared with traditional CABG.

265 Patients were randomly assigned to undergo CABG and receive medical therapy or to receive medical t

266 We randomly assigned patients undergoing CABG at 16 Veterans Affairs cardiac surgery centers to e

267 ic Surgeons database for patients undergoing CABG between 2011 and 2018.

268 s and outcomes of 42,714 patients undergoing CABG from 2005 through 2012.

269 1-year LDL-C >=70 mg/dl, patients undergoing CABG had significantly lower MACCE rates as compared wit

270 ements in the outcome of patients undergoing CABG surgery in the past decade, graft patency remains t

271 t clinical conditions in patients undergoing CABG surgery.

272 om >$15,000 per year for patients undergoing CABG to approximately $30,000 per year for patients unde

273 Among patients undergoing CABG, we did not find a significant difference between o

274 ng PCI and decreased for patients undergoing CABG.

275 cial and Medicare Advantage plans undergoing CABG (n=11 208) or AVR (n=6122) in 33 nonfederal acute c

276 Among them, 209 patients underwent CABG and 209 FFR-guided PCI.

277 ient Sample to select patients who underwent CABG between January 1, 2003, and December 31, 2014.

278 Before matching, patients who underwent CABG were significantly younger (age 65.7 years vs. 68.3

279 ft main CAD randomized to PCI (n=914) versus CABG (n=926) had angiographic core laboratory SS assessm

280 heart team when deciding between PCI versus CABG for revascularization in patients with left main CA

281 d early and long-term outcomes of PCI versus CABG in patients with diabetes.

282 patients with LMCAD treated with PCI versus CABG.

283 ention with everolimus-eluting stents versus CABG in patients with left main disease.

284 of PCI with everolimus-eluting stents versus CABG were consistent in diabetic and nondiabetic patient

285 to PCI with everolimus-eluting stents versus CABG, stratified by the presence of diabetes.

286 interval: 0.40 to 0.91; p = 0.016), whereas CABG was associated with improved outcomes across all 1-

287 It is not known, however, whether CABG confers a survival benefit after an extended follow

288 betes, who have fared relatively better with CABG in most prior trials, is unknown.

289 and cost-effectiveness of HCR compared with CABG and multivessel PCI alone.

290 erebrovascular events with PCI compared with CABG rose progressively with the SS.

291 PCI, compared with CABG, was associated with a similar risk of all-cause mo

292 significantly higher with PCI compared with CABG.

293 or clinical outcome at 5 years compared with CABG.

294 flow reserve (FFR)-guided PCI compared with CABG.

295 erapy that demonstrate survival effects with CABG also demonstrate infarct reduction.

296 ant trend toward a better MACCE outcome with CABG and a significant reduction in subsequent revascula

297 DM and MVD, coronary revascularization with CABG leads to lower all-cause mortality than with PCI-DE

298 e reductions in MACE and death in those with CABG preceding the ACS event.

299 patients with left main disease treated with CABG in the EXCEL trial, off-pump surgery was associated

300 contemporary cohort of patients treated with CABG.